BI 224436

BI 224436
	File:BI 224436.svg
Systematic (IUPAC) name
	(2S)-[4-(3,4-Dihydro-2H-chromen-6-yl)-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid
Clinical data
Legal status	Investigational;
Pharmacokinetic data
Biological half-life	7 hrs (simulated)
Identifiers
ATC code	none
ChemSpider	27289461
Chemical data
Formula	C24H25NO4
Molecular mass	391.460 g/mol
	SMILES CC(C)(C)O[C@@H](c1cnc2ccccc2c1c3ccc4c(c3)CCCO4)C(=O)O ;
	InChI InChI=1S/C24H25NO4/c1-24(2,3)29-22(23(26)27)18-14-25-19-9-5-4-8-17(19)21(18)16-10-11-20-15(13-16)7-6-12-28-20/h4-5,8-11,13-14,22H,6-7,12H2,1-3H3,(H,26,27)/t22-/m0/s1 ; Key:DMWVBLFYARRIDL-QFIPXVFZSA-N ;

BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.^[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.^[3]^[4]

References

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.